Salud financiera de hoja de balance de Paragon 28

Salud financiera controles de criterios 3/6

Paragon 28 tiene un patrimonio de los accionistas total de $177.7M y una deuda total de $110.4M, lo que sitúa su ratio deuda-patrimonio en 62.1%. Sus activos y pasivos totales son $340.7M y $163.0M respectivamente.

Información clave

62.1%

Ratio deuda-patrimonio

US$110.44m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$75.64m
Patrimonio	US$177.74m
Total pasivo	US$162.96m
Activos totales	US$340.70m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Many Still Looking Away From Paragon 28, Inc. (NYSE:FNA)

Apr 17

Paragon 28, Inc. (NYSE:FNA) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 03

After Leaping 29% Paragon 28, Inc. (NYSE:FNA) Shares Are Not Flying Under The Radar

Nov 28

US$25.00: That's What Analysts Think Paragon 28, Inc. (NYSE:FNA) Is Worth After Its Latest Results

May 12

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($215.8M) de FNA superan a sus pasivos a corto plazo ($51.2M).

Pasivo a largo plazo: Los activos a corto plazo de FNA ($215.8M) superan a sus pasivos a largo plazo ($111.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (19.6%) de FNA se considera satisfactorio.

Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de FNA se ha reducido en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: FNA tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: FNA tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 57.8% cada año

Salud financiera de hoja de balance de Paragon 28

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Many Still Looking Away From Paragon 28, Inc. (NYSE:FNA)

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc. to Report Q1, 2024 Results on May 08, 2024

New minor risk - Share price stability

Paragon 28, Inc. Announces Chief Financial Officer Changes

Paragon 28, Inc. Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler®? R3INFORCE™? Extraosseous Repair System

New major risk - Financial position

Co-Founder recently bought US$255k worth of stock

Consensus EPS estimates fall by 24%

Paragon 28, Inc. (NYSE:FNA) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS misses analyst expectations

Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Paragon 28, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Paragon 28, Inc. Launches Precision®? Mis Bunion System Offering Surgeons A Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

Paragon 28, Inc. Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

New minor risk - Shareholder dilution

Paragon 28, Inc. Launches the Mister Tendon™ Harvester System – the First and Only Minimally Invasive Harvesting System for Fhl and Fdl Tendon Transfer Procedures

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Paragon 28, Inc. Announce the Launch of the Grappler Knotless Anchor System and Bridgeline Tape

After Leaping 29% Paragon 28, Inc. (NYSE:FNA) Shares Are Not Flying Under The Radar

Paragon 28, Inc. Launches Beast Cortical Fibers

Third quarter 2023 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2022)

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2023

Price target decreased by 8.4% to US$25.00

Paragon 28, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Paragon 28®, Inc. Receives FDA Approval for Ide Feasibility Study of Its Smart Total Talus™ System for Use in Conjunction with the Apex 3D™ Total Ankle Replacement System

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

Paragon 28, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

Paragon 28, Inc. Provides Revenue Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 30%

Full year 2022 earnings: EPS misses analyst expectations

Paragon 28, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Paragon 28, Inc. has completed a Follow-on Equity Offering in the amount of $110.5 million.

Paragon 28 announces public offering of 6.5M shares

Paragon 28, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full-Year Ended December 31, 2022

Paragon 28 guides Q4 and FY22 revenue outlook above consensus

Chief Commercial Officer exercised options and sold US$1.8m worth of stock

Paragon 28, Inc. Enters Settlement Agreement with Stryker Corp

Consensus forecasts updated

Insider recently sold US$1.1m worth of stock

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Paragon 28, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year of 2022

Insider recently sold US$1.1m worth of stock

Paragon 28 GAAP EPS of -$0.13 misses by $0.01, revenue of $46M beats by $3.52M

Paragon 28, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Commercial Officer exercised options and sold US$59k worth of stock

Consensus forecasts updated

Paragon 28, Inc. Announces Board Changes

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Paragon 28, Inc. Revises Revenue Guidance for the Full Year 2022

Paragon 28, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Paragon 28, Inc.(NYSE:FNA) dropped from Russell 2500 Value Index

Key Executive recently sold US$379k worth of stock

Paragon 28, Inc. Launches Monkey Rings™ Circular External Fixation System

Key Executive recently sold US$450k worth of stock

Paragon 28, Inc. Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

Consensus forecasts updated

US$25.00: That's What Analysts Think Paragon 28, Inc. (NYSE:FNA) Is Worth After Its Latest Results

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Paragon 28, Inc. Provides Revenue Guidance for the Full Year 2022

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

High number of new directors

Paragon 28, Inc. Launches R3ACT™ Stabilization System for Ankle Injuries

Paragon 28, Inc. to Report Q1, 2022 Results on May 09, 2022

Paragon 28, Inc. Announces Executive Changes

Paragon 28, Inc., Annual General Meeting, May 18, 2022

Paragon 28, Inc. Announces Appointment of Meghan Scanlon to Board of Directors

Full year 2021 earnings: EPS misses analyst expectations

Paragon 28, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2021